Thermo Fisher Sci. stock (US8835561023): HSBC downgrade and target cut put focus on valuation

Thermo Fisher Sci. shares on the NYSE traded lower on 06/03/2026 after HSBC lowered its rating to Hold and cut its price target, putting renewed attention on the US life-sciences group’s growth outlook and valuation.

Thermo Fisher Sci. shares on the New York Stock Exchange were quoted around USD 471.50 on 06/03/2026, down about 2.2% on the day, as the US life-sciences supplier reacted to fresh analyst commentary, according to MarketBeat data as of 06/03/2026 and intraday pricing on MarketBeat.

The company, a major constituent of the US health care sector, drew attention from domestic and international investors after HSBC lowered its rating on Thermo Fisher Sci. to Hold from Buy and cut its price target to USD 540 from USD 670 in a research note published on 06/03/2026, as reported by MT Newswires via MarketScreener.

HSBC’s move added to a series of recent revisions by Wall Street banks, including a Wells Fargo adjustment that trimmed its price target for Thermo Fisher Sci. to USD 615 with an Overweight stance, according to a MarketBeat summary of analyst actions as of 06/03/2026.

Based on consensus data compiled by MarketBeat as of 06/03/2026, Thermo Fisher Sci. still carries a Moderate Buy rating from 24 analysts, with an average 12-month price target of roughly USD 613.67, indicating that the latest HSBC downgrade sits toward the cautious end of the target range.

The stock’s home-market relevance remains centered on the United States, where Thermo Fisher Sci. is listed on the NYSE under the ticker TMO and is widely held by US institutions, including a sizable position by Bank of New York Mellon, which recently increased its stake according to a filing report summarized by MarketBeat on 06/03/2026.

In a European context, the stock also changes hands on German trading venues via secondary listings, offering euro-based investors access to the US group, although liquidity and reference pricing remain anchored in the United States through its NYSE listing.

The price reaction on 06/03/2026 followed a period during which Thermo Fisher Sci. shares had traded between a 52-week low near USD 385.72 and a 52-week high around USD 643.99, according to live-quote data from Moneycontrol as of 06/03/2026, underlining the stock’s notable volatility over the past year.

As of: 03.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Thermo Fisher
• Sector/industry: Life sciences tools and diagnostics
• Headquarters/country: Waltham, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Analytical instruments, specialty diagnostics, lab products and biopharma services
• Home exchange/listing venue: NYSE (TMO)
• Trading currency: USD

Thermo Fisher Sci.: core business model

Thermo Fisher Sci. operates as a global provider of laboratory instruments, diagnostics, consumables and contract services that support research, clinical testing and biopharmaceutical production across major healthcare and industrial markets worldwide.

Thermo Fisher Sci. in peer comparison

When compared with US-listed peers in the life sciences tools and diagnostics space, Thermo Fisher Sci. is often benchmarked against players such as Danaher and Agilent Technologies, which likewise serve pharmaceutical, biotechnology and clinical laboratory customers with instruments, consumables and related services, according to sector overviews from MarketScreener and other analyst compilations as of 06/03/2026.

While detailed valuation metrics for each of these companies vary over time, consensus data from MarketBeat as of 06/03/2026 indicate that Thermo Fisher Sci. trades with a Moderate Buy rating and an average price target of about USD 613.67 from 24 analysts, a profile that positions it broadly in line with other large US life-sciences tool providers in terms of analyst sentiment and implied upside from current levels.

Conclusion

The 06/03/2026 trading session for Thermo Fisher Sci. in the United States was shaped by HSBC’s downgrade to Hold and price-target cut to USD 540, weighing on the NYSE-listed shares and highlighting investor sensitivity to changes in analyst views.

Placed alongside peers in the life-sciences tools space, Thermo Fisher Sci. continues to be covered by a broad analyst base, with consensus data pointing to a Moderate Buy stance and an average target near USD 613.67, suggesting that opinions differ on how near-term growth risks balance against the company’s scale and market position.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.